Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Northrop Grumman Corporation — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while Northrop Grumman Corporation trades at $500 (market cap $70.42B). The key difference: Northrop Grumman Corporation is far larger — about 7.9× Kymera Therapeutics Inc. Common Stock's market cap, and Northrop Grumman Corporation pays a 1.99% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Northrop Grumman Corporation for 82 Days on average.
| KYMR | NOC | |
|---|---|---|
Market Cap | $8.88B | $70.42B |
Volume | 1,028,790 | 1,218,886 |
Sector | Health | Industrials |
52-Week High | $127.31 | $768.02 |
52-Week Low | $55.80 | $473.46 |
Typical Hold Time | 0 Days | 82 Days |
Enterprise Value | $8.27B | $84.40B |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Northrop Grumman (NOC) trades at $481.38, down 0.75% with bearish technical signals despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $7.68 exceeding expectations by 13%. Revenue growth remains steady, reaching $41.95B in 2025, while maintaining healthy profitability with 10.48% net margins. Recent news highlights both competitive challenges from Boeing's $20B fighter contract win and positive developments including new defense awards and record backlog.
The investment case balances strong fundamentals against near-term headwinds. Analyst consensus remains bullish with a $595.69 price target (24% upside), though technical indicators suggest caution. Key opportunities include defense budget tailwinds and B-21/Sentinel programs, while risks involve contract competition and execution challenges in major defense programs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
